Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet., Nov (2012)
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.
Ann. Oncol., Nov (2012)
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Ann. Oncol., Dec;23(12):3180-7 (2012)
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Eur. J. Cancer., Nov;48(16):3036-44 (2012)
Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.
J. Am. Coll. Surg., Jul;215(1):53-9; discussion 59-60 (2012)
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
Clin. Cancer Res., Jun;18(11):3170-9 (2012)
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
J. Clin. Oncol., Jul;30(19):2401-7 (2012)
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial.
Cancer., Dec;118(23):5894-902 (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet., May;379(9829):1879-86 (2012)
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
Cancer., Nov;118(21):5403-13 (2012)
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
Nature., Mar;483(7391):613-7 (2012)
Imaging features of bone metastases in patients with gastrointestinal stromal tumors.
Diagn Interv Radiol., 18(4):391-6 (2012 Jul-Aug)
mTOR inhibitors in sarcoma.
Clin Adv Hematol Oncol., Feb;9(2):145-7 (2011)
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
PLoS ONE., 7(2):e26331 (2012)
First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
Eur. J. Cancer., Mar;48(4):547-63 (2012)
NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.
J Natl Compr Canc Netw., Dec;9 Suppl 6:S1-16 (2011)
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Ann. Surg. Oncol., Apr;19(4):1074-80 (2012)
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
J. Clin. Oncol., Jan;30(1):78-84 (2012)
Aberrant AKT activation drives well-differentiated liposarcoma.
Proc. Natl. Acad. Sci. U.S.A., Sep;108(39):16386-91 (2011)
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
Cancer., Feb;118(3):770-6 (2012)